

Review of: "Targeting Alzheimer's disease hallmarks with the Nrf2 activator Isoeugenol"

Bruce Teter¹

¹ University of California, Los Angeles

Potential competing interests: No potential competing interests to declare.

This is a well conducted study of a new Nrf2 activator, Isoeugenol. The study demonstrates beneficial activity of Iso in a mouse model of AD, and in in vitro studies, such that Iso ameliorated biochemical, gene expression, and behavioral endpoints relevant to AD. Multiple levels of analysis contribute to a very thorough drug study. The data are presented well and with appropriate statistical analysis, and results are integrated with each other, and discussed with respect to the published literature of the field.